Maraviroc nonresponders show increased CXCR3 chemokines and IL-15. (A) Day 30 serum levels of IL-15 from maraviroc-treated patients who developed or did not develop grade 2-4 acute GVHD by day 180. (B) Correlation of IL-15 concentration and percentage of CD38⁺CD4⁺ T cells at day 30 (r, Pearson’s correlation coefficient). (C-G) Day 30 serum levels of CCL3 (C), CCL4 (D), CCL5 (E), CXCL9 (F), CXCL10 (G) from maraviroc-treated patients who developed or did not develop grade 2-4 GVHD by day 180. (H) Correlation of CXCL9 concentration and percentage of CD38⁺CD4⁺ T cells at day 30. (I) Correlation of CXCL10 concentration and percentage of CD38⁺CD4⁺ T cells at day 30. *P < .05, **P < .01, Student t test.